A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

January 10, 2026

Study Completion Date

March 10, 2026

Conditions
MalariaMalaria,FalciparumParasitic DiseaseVector Borne DiseasesInfections
Interventions
BIOLOGICAL

RH5.1 and/or RH5.2-VLP with Matrix-M

"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The RH5.2 protein consists of the stabilised core region of PfRH5 antigen with SpyTag fused at the C-terminus. The RH5.2-SpyTag protein is conjugated to hepatitis B surface antigen (HBsAg)-SpyCatcher to produce the final RH5.2-VLP vaccine.~The Matrix-M has been developed and manufactured by Novavax AB and is presented as a liquid solution in a glass vial."

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT05978037 - A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines | Biotech Hunter | Biotech Hunter